Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Emory University | 24 |
| 2 | Sumitomo Chemical Co Ltd | 18 |
| 3 | Sanofi SA | 10 |
| 4 | Sumitomo Seika Chemicals Co Ltd | 9 |
| 5 | Pfizer Inc | 8 |
| 6 | Chugoku Marine Paints Ltd | 6 |
| 7 | Centre National de la Recherche Scientifique | 5 |
| 8 | Fujifilm Holdings Corp | 4 |
| 9 | Institut National de la Santé et de la Recherche Médicale | 4 |
| 10 | Northwestern University | 3 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 87 |
| 2 | A61P | Therapeutic activity (drug indications) | 82 |
| 3 | C07D | Heterocyclic compounds | 58 |
| 4 | C07C | Acyclic and carbocyclic compounds | 22 |
| 5 | Y02A | Climate change adaptation | 19 |
| 6 | A01N | Preservation of bodies; biocides; pest repellents | 16 |
| 7 | C07K | Peptides | 12 |
| 8 | C09D | Coatings, paints, varnishes | 9 |
| 9 | G01N | Investigating / analysing materials | 9 |
| 10 | C12N | Microorganisms, enzymes | 8 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | 2020 | Emory University | 41 |
| NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | 2022 | Emory University | 16 |
| MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | 2022 | Emory University | 13 |
| IDENTIFICATION OF SMALL MOLECULE INHIBITORS OF JUMONJI AT-RICH INTERACTIVE DOMAIN 1A (JARID1A) AND 1B (JARID1B) HISTONE DEMETHYLASE | 2014 | Yale University | 37 |
| THIONUCLEOSIDES AS ANTIVIRAL AGENTS | 2022 | Emory University | 12 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Larry A. Sklar | University of New Mexico | 3 |
| 2 | Matthew Saunders | University of New Mexico | 3 |
| 3 | Steven W. Graves | Los Alamos National Laboratory | 3 |
| 4 | Bruce S. Edwards | University of New Mexico | 3 |
| 5 | Eduard Sergienko | Sanford Burnham Prebys Medical Discovery Institute | 2 |
| 6 | Jennifer E. Golden | University of Wisconsin–Madison | 2 |
| 7 | Warren S. Weiner | University of Kansas | 2 |
| 8 | Layton H. Smith | Sanford Burnham Prebys Medical Discovery Institute | 2 |
| 9 | James C. Morris | Clemson University | 2 |
| 10 | Nicholas D. P. Cosford | Sanford Burnham Prebys Medical Discovery Institute | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Inhibition of Superoxide and Nitric Oxide Release and Protection From Reoxygenation Injury by Ebselen in Rat Kupffer Cells | 1992 | 98 | Redox biology and oxidative stress |
| In vitro assessment of the growth and plasma membrane H+‐ATPase inhibitory activity of ebselen and structurally related selenium‐ and sulfur‐containing compounds in Candida albicans | 2017 | 27 | Antifungal resistance and susceptibility |
| Inhibition of superoxide anion radical production by ebselen (PZ51) and its sulfur analogue (PZ25) in guinea pig alveolar macrophages. | 1989 | 10 | Sulfur Compounds in Biology |
| Mechanism for the inhibitory effect of a seleno-organic compound, Ebselen, and its analogues on superoxide anion production in guinea pig polymorphonuclear leukocytes. | 1990 | 9 | Selenium in Biological Systems |
| pH-Partition profiles of 4-(3-oxo-1,2-benzisothiazolin-2-yl)phenyl and phenoxyalkanoic acids | 2003 | 5 | Synthesis and biological activity |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Ebsulfur?
Which organizations hold the most patents containing Ebsulfur?
What are the primary patent classifications for Ebsulfur compounds?
How has patent activity for Ebsulfur changed over time?
What research topics are associated with Ebsulfur in the academic literature?